Dose-Dependent Therapeutic Distinction between Active and Passive Targeting Revealed Using Transferrin-Coated PGMA Nanoparticles. (Q38815759)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26619362 AND SRC:MED&resulttype=core&format=json

1 March 2020

title

Dose-Dependent Therapeutic Distinction between Active and Passive Targeting Revealed Using Transferrin-Coated PGMA Nanoparticles (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26619362 AND SRC:MED&resulttype=core&format=json

1 March 2020

0 references

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26619362 AND SRC:MED&resulttype=core&format=json

1 March 2020

Tim St Pierre

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26619362 AND SRC:MED&resulttype=core&format=json

1 March 2020

Nicole M Smith

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26619362 AND SRC:MED&resulttype=core&format=json

1 March 2020

Lee Yong Lim

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26619362 AND SRC:MED&resulttype=core&format=json

1 March 2020

author name string

Ruhani Singh

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26619362 AND SRC:MED&resulttype=core&format=json

1 March 2020

Marck Norret

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26619362 AND SRC:MED&resulttype=core&format=json

1 March 2020

Michael J House

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26619362 AND SRC:MED&resulttype=core&format=json

1 March 2020

Yuriy Galabura

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26619362 AND SRC:MED&resulttype=core&format=json

1 March 2020

Michael Bradshaw

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26619362 AND SRC:MED&resulttype=core&format=json

1 March 2020

Robert C Woodward

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26619362 AND SRC:MED&resulttype=core&format=json

1 March 2020

Killugudi Swaminathan Iyer

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26619362 AND SRC:MED&resulttype=core&format=json

1 March 2020

Igor Luzinov

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26619362 AND SRC:MED&resulttype=core&format=json

1 March 2020

publication date

30 November 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26619362 AND SRC:MED&resulttype=core&format=json

1 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26619362 AND SRC:MED&resulttype=core&format=json

1 March 2020

volume

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26619362 AND SRC:MED&resulttype=core&format=json

1 March 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26619362 AND SRC:MED&resulttype=core&format=json

1 March 2020

page(s)

351-359

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26619362 AND SRC:MED&resulttype=core&format=json

A review of current nanoparticle and targeting moieties for the delivery of cancer therapeutics

1 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1002/SMLL.201502730

Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/SMLL.201502730

To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/SMLL.201502730

Exploiting the enhanced permeability and retention effect for tumor targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/SMLL.201502730

Tumorigenesis and the angiogenic switch

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/SMLL.201502730

Active targeting schemes for nanoparticle systems in cancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/SMLL.201502730

A reexamination of active and passive tumor targeting by using rod-shaped gold nanocrystals and covalently conjugated peptide ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/SMLL.201502730

Mechanism of active targeting in solid tumors with transferrin-containing gold nanoparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/SMLL.201502730

Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/SMLL.201502730

Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/SMLL.201502730

Biomolecular coronas provide the biological identity of nanosized materials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/SMLL.201502730

Understanding biophysicochemical interactions at the nano-bio interface

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/SMLL.201502730

21 January 2018

Cancer statistics, 2014

1 reference

https://api.crossref.org/works/10.1002/SMLL.201502730

Bypass Mechanisms of the Androgen Receptor Pathway in Therapy-Resistant Prostate Cancer Cell Models

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/SMLL.201502730

Castration-resistant prostate cancer: mechanisms, targets, and treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/SMLL.201502730

Castration-resistant prostate cancer: AUA Guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/SMLL.201502730

Drug resistance in metastatic castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/SMLL.201502730

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/SMLL.201502730

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/SMLL.201502730

Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/SMLL.201502730

In vitro targeting of synthesized antibody-conjugated dendrimer nanoparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/SMLL.201502730

Aptamer-conjugated and doxorubicin-loaded unimolecular micelles for targeted therapy of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/SMLL.201502730

Targeted biocompatible nanoparticles for the delivery of (-)-epigallocatechin 3-gallate to prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/SMLL.201502730

Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/SMLL.201502730

Molecular characterization of human prostate carcinoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/SMLL.201502730

PC3 is a cell line characteristic of prostatic small cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/SMLL.201502730

Unique patterns of molecular profiling between human prostate cancer LNCaP and PC-3 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/SMLL.201502730

Decreased replication ability of E1-deleted adenoviruses correlates with increased brain tumor malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/SMLL.201502730

Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/SMLL.201502730

Annotating MYC status with 89Zr-transferrin imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/SMLL.201502730

Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/SMLL.201502730

Epidermal growth factor-ferritin H-chain protein nanoparticles for tumor active targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/SMLL.201502730

Ligand-targeted particulate nanomedicines undergoing clinical evaluation: current status

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/SMLL.201502730

Induced clustered nanoconfinement of superparamagnetic iron oxide in biodegradable nanoparticles enhances transverse relaxivity for targeted theranostics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/SMLL.201502730

Dose translation from animal to human studies revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/SMLL.201502730

siRNA screen of the human signaling proteome identifies the PtdIns(3,4,5)P3-mTOR signaling pathway as a primary regulator of transferrin uptake

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/SMLL.201502730

Myc-driven murine prostate cancer shares molecular features with human prostate tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/SMLL.201502730

Prevalence and management of cancer-related anaemia, iron deficiency and the specific role of i.v. iron

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/SMLL.201502730

Monodisperse MFe2O4 (M = Fe, Co, Mn) nanoparticles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/SMLL.201502730

Enhanced antiproliferative activity of transferrin-conjugated paclitaxel-loaded nanoparticles is mediated via sustained intracellular drug retention

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/SMLL.201502730

21 January 2018

Identifiers

DOI

10.1002/SMLL.201502730

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26619362 AND SRC:MED&resulttype=core&format=json

1 March 2020

1 reference